TotipotentRx

What TotipotentRx does

TotipotentRx (operating as TotipotentRX Cellular Medicine, BVI-incorporated) is a biomedical technology company founded in 2011 in Los Angeles, California, and currently a subsidiary of Cesca Therapeutics Inc. (formerly ThermoGenesis Corp., NASDAQ: KOOL). It engages in the research, development, and commercialization of cell-based therapeutics for regenerative medicine, with a portfolio of FDA 510(k)-cleared point-of-care medical device kits and proprietary cell-processing platforms including POCXpress™, AutoXpress® (AXP), PXP™, MXP™, and the VXP System paired with the SurgWerks™-CLI Kit. The technology isolates regenerative cells from bone marrow or blood in 20–60 minutes for autologous cell-based therapies targeting critical limb ischemia, cardiovascular disease, osteoarthritis, diabetic foot ulcers, and wound care indications.

The company operates three revenue streams: (1) hardware sales of Class I, II, and IIb point-of-care cell therapy kits sold directly to clinicians and hospitals; (2) contract clinical trial services (CRO) for cellular therapy sponsors, run primarily out of Gurugram, India at approximately 80% lower cost than U.S. equivalents; and (3) automated clinical biobanking and cell manufacturing services for immuno-oncology applications. The CRO offering is full-service, covering trial design, protocol writing, site selection, ethics submissions, monitoring, data management, statistical analysis, and medical writing, with multi-year quote-based engagements. Operations are GxP-compliant and CFR 21 Part 11 compliant across facilities in Irvine CA, Rancho Cordova CA, Gurugram India, and Tianjin China (the latter via the ImmuneCyte subsidiary's 2021 acquisition of Boyalife Genomics).

The corporate group has undergone multiple restructurings, including the 2013 merger with ThermoGenesis Corp., the 2019 spin-off of clinical assets into ImmuneCyte Inc., and ongoing shared governance between TotipotentRx leadership (Chairman/CEO Chris Xu, President Haihong Zhu, CFO Jeff Cauble) and ThermoGenesis Holdings Inc. (NASDAQ: THMO). Clinical progression includes publication of 40-month Phase I/II CLI data (2016), FDA acceptance of the amended Phase III CLIRST trial design (2017), and ongoing Phase III enrollment for critical limb ischemia using the VXP System with the SurgWerks-CLI Kit.

Name

TotipotentRx

Legal name

TotipotentRX Cellular Medicine Inc (BVI)

Website

https://totipotentrx.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

TotipotentRx is a biomedical technology subsidiary of Cesca Therapeutics that develops FDA-cleared point-of-care cell therapy kits and autologous regenerative medicine platforms, serving cellular therapy developers, biotech sponsors, hospitals, and clinicians across the US, India, and China.

Ownership category

akta.pro rank

Product category

Cell Therapy Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Cell therapy manufacturing
• Regenerative medicine devices
• Point-of-care cell processing
• Autologous stem cell therapy
• Clinical trial services

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Cell Therapy Product (Kits) Sales: Develops and markets complete point-of-care kits (Class I, II and IIb) for the harvesting and processing of cellular therapeutics. Revenue generated through one-time hardware sales of POCXpressTM platform devices and procedure kits.
2. Clinical Trial Services (CRO): Provides both a la carte and end-to-end clinical trial services for cellular therapy products and medical devices, including trial design, protocol writing, sites selection, ethic-administrative submissions, monitoring, data management, statistical analysis and medical writing. Conducted primarily in India at 80% lower cost than U.S. trials.
3. Automated Clinical Biobanking & Cell Manufacturing Services: Provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Includes cell manufacturing, cryopreservation and long-term storage of samples.

Pricing tiers

Go-to-market motion2 records

Core offering

TotipotentRx develops and commercializes complete Class I, II and IIb point-of-care kits (POCXpressTM platform) for the harvesting and processing of cellular therapeutics, used to manufacture autologous cell-based product candidates for endo- and cardiovascular, orthopedic, diabetic foot ulcer and wound care indications. The company also provides contract clinical trial services for cellular therapy developers and medical device manufacturers, leveraging India-based operations to deliver Phase I & II trials at roughly 80% lower cost than U.S. equivalents.

Product overview

TotipotentRx (operating as TotipotentRX Cellular Medicine) offers a platform-plus-modules architecture centered on the proprietary POCXpressTM Point-of-Care cell therapy manufacturing platform, which integrates with the company's broader portfolio of automated, closed-system cell-processing technologies — notably the AutoXpress® (AXP) Technology Platform and the PXP™ Technology Platform — together with associated device systems (VXP System, MXP™ System) and clinical product kits such as the SurgWerks-CLI Kit. The core POCXpressTM Platform serves as the unifying automated manufacturing layer for cell-based therapeutics at the point of care, while the AXP and PXP platforms provide the underlying cell-processing capabilities and the VXP/MXP systems act as sub-modules used within specific clinical workflows (e.g., critical limb ischemia and osteoarthritis). This technology stack is complemented by Clinical Trial Services (CRO offerings) that operationalize the platforms in sponsored regenerative medicine trials.

Differentiator

Problem solved

Functional benefit

Brands

• POCXpress: Proprietary point-of-care platform with multiple U.S. FDA 510(k) approved medical devices used to rapidly isolate regenerative cells from bone marrow or blood in 20-60 minutes; supports manufacture of therapeutic product candidates for endo- and cardiovascular diseases, orthopedic diseases, diabetic foot ulcer and wound care.

Products and services

• POCXpressTM Point-of-Care Platform FDA 510(k) cleared medical device platform that rapidly isolates regenerative cells from bone marrow or blood in less than 20-60 minutes, used to manufacture autologous cell-based therapeutic product candidates for endo- and cardiovascular, orthopedic, diabetic foot ulcer and wound care indications. Sold to clinicians, hospitals and cellular therapy developers.
• Cell Therapy Product Kits (Class I, II, IIb) A portfolio of complete point-of-care kits classified as Class I, II and IIb medical devices for the harvesting and processing of cellular therapeutics, sold directly to clinicians and hospitals for regenerative medicine applications.
• SurgWerks™-CLI Kit with VXP System Bone marrow processing system paired with the SurgWerks-CLI Kit aspiration trocar and Therapeutic Infusion Needles used to deliver autologous bone marrow concentrate for treatment of critical limb ischemia in the Phase III CLIRST trial.
• Clinical Trial Services (CRO) End-to-end and a la carte clinical trial services for cellular therapy products and medical devices, including trial design, protocol writing, site selection, ethics-administrative submissions, monitoring, data management, statistical analysis and medical writing, delivered primarily from India at approximately 80% lower cost than U.S. trials.
• Automated Clinical Biobanking & Cell Manufacturing Services Full suite of solutions for automated clinical biobanking, point-of-care cell processing and automation for immuno-oncology, including cell manufacturing, cryopreservation and long-term storage of samples.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Lonza Cell & Gene Technologies: Global cell and gene therapy CDMO offering autologous and allogeneic manufacturing services. Comparable to TotipotentRx's CRO/cell manufacturing services arm and its automated cell processing platform strategy, but at vastly larger scale and broader modality coverage.
• Catalent (Cell Therapy): Offers cell therapy development, manufacturing, and analytical services for autologous and allogeneic therapies, comparable in service scope to TotipotentRx's CRO/manufacturing arm, with broader geographic and modality coverage.
• Cytiva: Provides cell therapy manufacturing platforms (Sefia, Xuri), automation, and processing instruments to cell therapy developers. Overlaps with TotipotentRx's automated closed-system cell processing business and serves the same developer/sponsor customer base.
• Fresenius Kabi (Cell Therapy): Provides cell therapy collection, processing, and cryopreservation products and services, including point-of-care and decentralized manufacturing systems. Comparable to TotipotentRx's kit-based cell processing offering for hospitals and sponsors.
• Thermo Fisher Scientific (Patheon / Cell Therapy Services): Operates a large cell therapy services and CDMO business through Patheon, providing clinical and commercial cell therapy manufacturing comparable to TotipotentRx's CRO and biobanking offerings, with significantly broader scale.

Direct peers

• Miltenyi Biotec: Manufactures closed-system cell processing devices, reagents, and instruments (e.g., Prodigy, CliniMACS) used to isolate and process cells for cell and gene therapy. Direct comparable to TotipotentRx's POCXpress, AutoXpress, and VXP point-of-care cell processing platforms.
• Bio-Techne: Sells GMP-grade cytokines, media, reagents, and cell processing tools used in cell therapy manufacturing workflows, overlapping with TotipotentRx's cell processing kits, ancillary materials, and point-of-care workflows.
• STEMCELL Technologies: Supplies cell isolation, processing, and culture products (including closed-system devices) to researchers and clinical cell therapy developers. Direct comparable to TotipotentRx's point-of-care cell isolation and processing kit business.
• Cesca Therapeutics (parent) / ThermoGenesis Holdings: Public parent of TotipotentRx developing AXP, PXP, and VXP cell processing systems for cord blood and clinical cell therapy. Directly comparable technology and customer overlap with TotipotentRx's autologous point-of-care cell processing platform.

Emerging players

• Pluristem Therapeutics: Clinical-stage cell therapy developer working on placental-derived cell therapies for peripheral and vascular indications. Comparable therapeutic-area overlap with TotipotentRx's CLI/cardiovascular pipeline, though using an off-the-shelf allogeneic rather than autologous approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TotipotentRx